Latest News of ALNY
Russian dissident Alex Navalny always knew he would die
By New York Post |
1 week ago
Alexei Navalny, a vocal critic of Vladimir Putin, faced numerous challenges, including surviving a poisoning attempt and unjust imprisonments. Despite the risks, he remained dedicated to his fight aga...
Patriot by Alexei Navalny review - the man who dared to defy Putin
By The Guardian |
1 week ago
Alexei Navalny's memoir, "Patriot," recounts his remarkable life from childhood near Chornobyl to surviving a novichok attack and imprisonment in an Arctic penal colony....
Russia's exiled opposition rocked by claims over hammer attack on Navalny ally
By The Guardian |
1 month ago
Allegations against Kremlin critic Leonid Nevzlin ordering an attack on Volkov have caused turmoil in the Russian opposition. The accusations, based on leaked messages, have led to infighting and disb...
-
Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Bullish on This Aggressive Growth Stock
By Yahoo! Finance | 1 month agoInsider Monkey compiled a list of top aggressive growth stocks favored by hedge funds, including Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). It discusses the valuation methods for high-growth stocks ...
-
Infighting rocks Russia's exiled opposition as Navalny allies accuse colleagues of foul play
By Reuters | 1 month agoBy Andrew Osborn and Lucy PapachristouLONDON (Reuters) -Splits in Russia's opposition in exile have widened sharply, shifting their focus from political activism to infighting after allies of late opp...
-
Alnylam Pharmaceuticals, Inc. (ALNY): Do Hedge Funds Recommend This Biotech Stock Now?
By Yahoo! Finance | 1 month agoA list of top biotech stocks favored by hedge funds includes Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), known for RNA interference drugs. Despite some challenges, the company's strong performance in...
-
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
By Yahoo! Finance | 3 months agoAlnylam Pharmaceuticals is on track to reach breakeven point by 2026, with analysts predicting a profitable year ahead. The company's high growth rate of 63% per year could lead to earlier profitabili...
-
Alnylam Pharmaceuticals (NASDAQ:ALNY) rallies 3.8% this week, taking five-year gains to 246%
By Yahoo! Finance | 3 months agoInvesting in stocks carries risks of potential loss, but also the opportunity for high returns. Alnylam Pharmaceuticals has shown impressive growth in share price due to strong revenue growth, making ...
-
Pipeline Moves: Alnylam's Amvuttra approval prospects up after Phase III win
By Yahoo! Finance | 3 months agoAlnylam's Amvuttra shows promise in familial amyloid cardiomyopathy, Shionogi's S-309309 progresses in obesity, and Junshi Biosciences faces setbacks in ovarian cancer trials. These developments impac...
-
An Intrinsic Calculation For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Suggests It's 50% Undervalued
By Yahoo! Finance | 4 months agoThe fair value estimate for Alnylam Pharmaceuticals is 97% higher than analysts' price target. A Discounted Cash Flow (DCF) model is used to evaluate the company's investment potential. The valuation ...
-
Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran
By Yahoo! Finance | 4 months agoAlnylam Pharmaceuticals experienced a 32% surge in stock value due to successful Phase III trial results of vutrisiran for treating ATTR-CM. The study showed significant reductions in mortality and ca...
-
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024
By AP NEWS | 4 months agoStocks showing notable activity on Monday include RXO Inc. acquiring UPS' freight-brokerage business, Disney's "Inside Out 2" success, Apple facing EU digital competition accusations, ResMed slipping ...
-
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 4 months agoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company specializing in RNA interference therapeutics. They have a range of products for various diseases and strategic collaborations with industr...
-
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shift From Loss To Profit
By Yahoo! Finance | 4 months agoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company aiming to reach breakeven by 2025, with analysts projecting a profit of US$240m in 2026. The company's growth rate is estimated at 64%, ind...
-
U.S. intelligence believes Putin probably didn't order Navalny to be killed - WSJ
By Reuters | 6 months agoLONDON (Reuters) - U.S. intelligence agencies have determined that Russian President Vladimir Putin probably didn't order opposition politician Alexei Navalny killed at an Arctic prison camp in Fe...